Folgen
Monica Valeria Estrada
Monica Valeria Estrada
Bestätigte E-Mail-Adresse bei ucsd.edu
Titel
Zitiert von
Zitiert von
Jahr
Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection
BD Lehmann, B Jovanović, XI Chen, MV Estrada, KN Johnson, Y Shyr, ...
PloS one 11 (6), e0157368, 2016
12532016
Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data
F Finotello, C Mayer, C Plattner, G Laschober, D Rieder, H Hackl, ...
Genome medicine 11, 1-20, 2019
8572019
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology …
S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ...
Advances in anatomic pathology 24 (6), 311-335, 2017
6652017
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology …
S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ...
Advances in anatomic pathology 24 (5), 235-251, 2017
5972017
RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune …
S Loi, S Dushyanthen, PA Beavis, R Salgado, C Denkert, P Savas, ...
Clinical Cancer Research 22 (6), 1499-1509, 2016
5232016
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
DB Johnson, MV Estrada, R Salgado, V Sanchez, DB Doxie, SR Opalenik, ...
Nature communications 7 (1), 10582, 2016
5032016
MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation
K Lee, JM Giltnane, JM Balko, LJ Schwarz, AL Guerrero-Zotano, ...
Cell metabolism 26 (4), 633-647. e7, 2017
5022017
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2 Metastatic Breast Cancer
IA Mayer, VG Abramson, L Formisano, JM Balko, MV Estrada, ...
Clinical cancer research 23 (1), 26-34, 2017
3352017
Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer
VM Jansen, NE Bhola, JA Bauer, L Formisano, KM Lee, KE Hutchinson, ...
Cancer research 77 (9), 2488-2499, 2017
2162017
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
AG Sacco, R Chen, FP Worden, DJL Wong, D Adkins, P Swiecicki, ...
The Lancet Oncology 22 (6), 883-892, 2021
1392021
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
DB Johnson, MJ Nixon, Y Wang, DY Wang, E Castellanos, MV Estrada, ...
JCI insight 3 (24), 2018
1382018
Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence
JM Balko, LJ Schwarz, N Luo, MV Estrada, JM Giltnane, ...
Science translational medicine 8 (334), 334ra53-334ra53, 2016
1382016
Association of FGFR1 with ERα maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer
L Formisano, KM Stauffer, CD Young, NE Bhola, AL Guerrero-Zotano, ...
Clinical Cancer Research 23 (20), 6138-6150, 2017
1252017
A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC): responses and …
B Jovanović, IA Mayer, EL Mayer, VG Abramson, A Bardia, ME Sanders, ...
Clinical Cancer Research 23 (15), 4035-4045, 2017
1252017
Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance
JM Giltnane, KE Hutchinson, TP Stricker, L Formisano, CD Young, ...
Science translational medicine 9 (402), eaai7993, 2017
1182017
Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers
M Morrison Joly, DJ Hicks, B Jones, V Sanchez, MV Estrada, C Young, ...
Cancer research 76 (16), 4752-4764, 2016
1022016
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation
DP Kodack, V Askoxylakis, GB Ferraro, Q Sheng, M Badeaux, S Goel, ...
Science translational medicine 9 (391), eaal4682, 2017
1012017
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer
AB Hanker, MV Estrada, G Bianchini, PD Moore, J Zhao, F Cheng, ...
Cancer research 77 (12), 3280-3292, 2017
912017
Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2
BN Rexer, R Ghosh, A Narasanna, MV Estrada, A Chakrabarty, Y Song, ...
Clinical Cancer Research 19 (19), 5390-5401, 2013
812013
HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2
AB Hanker, JT Garrett, MV Estrada, PD Moore, PG Ericsson, JP Koch, ...
Clinical Cancer Research 23 (15), 4323-4334, 2017
792017
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20